PI3K mutations in breast cancer: prognostic and therapeutic implications

References

• SørlieTPerouCMTibshiraniRGene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProc Natl Acad Sci U S A20019819108691087411553815
   PubMed Web of Science ®Google Scholar
• GoldhirschAWoodWCCoatesASGelberRDThurlimannBSennHJStrategies for subtypes – dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Ann Oncol20112281736174721709140
   PubMed Web of Science ®Google Scholar
• SamuelsYWangZBardelliAHigh frequency of mutations of the PIK3CA gene in human cancersScience2004304567055415016963
   PubMed Web of Science ®Google Scholar
• LiuPChengHRobertsTMZhaoJJTargeting the phosphoinositide 3-kinase pathway in cancerNat Rev Drug Discov20098862764419644473
   PubMed Web of Science ®Google Scholar
• EngelmanJATargeting PI3K signalling in cancer: opportunities, challenges and limitationsNat Rev Cancer20099855056219629070
   PubMed Web of Science ®Google Scholar
• ZhaoJJLiuZWangLShinELodaMFRobertsTMThe oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cellsProc Natl Acad Sci U S A200510251184431844816339315
   PubMed Web of Science ®Google Scholar
• IsakoffSJEngelmanJAIrieHYBreast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cellsCancer Res20056523109921100016322248
   PubMed Web of Science ®Google Scholar
• MiledNYanYHonWCMechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunitScience2007317583523924217626883
   PubMed Web of Science ®Google Scholar
• HuangCHMandelkerDSchmidt-KittlerOThe structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutationsScience200731858571744174818079394
   PubMed Web of Science ®Google Scholar
• Gonzalez-AnguloAMChenHKaruturiMSFrequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancerCancer2013119171522736407
   PubMed Web of Science ®Google Scholar
• WuGXingMMamboESomatic mutation and gain of copy number of PIK3CA in human breast cancerBreast Cancer Res200575R609R61616168105
   PubMed Web of Science ®Google Scholar
• CizkovaMVacherSMeseureDPIK3R1 underexpression is an independent prognostic marker in breast cancerBMC Cancer20131354524229379
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• WallaschCWeissFUNiederfellnerGJallalBIssingWUllrichAHeregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3EMBO J19951417426742757556068
   PubMed Web of Science ®Google Scholar
• ZhangKSunJLiuNTransformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2J Biol Chem19962717388438908632008
   PubMed Web of Science ®Google Scholar
• Pinkas-KramarskiRLenferinkAEBacusSSThe oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulinOncogene19981610124912589546426
   PubMed Web of Science ®Google Scholar
• AlimandiMRomanoACuriaMCCooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomasOncogene1995109181318217538656
   PubMed Web of Science ®Google Scholar
• HynesNELaneHAERBB receptors and cancer: the complexity of targeted inhibitorsNat Rev Cancer20055534135415864276
   PubMed Web of Science ®Google Scholar
• KnuefermannCLuYLiuBHER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cellsOncogene200322213205321212761490
   PubMed Web of Science ®Google Scholar
• JunttilaTTAkitaRWParsonsKLigand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941Cancer Cell200915542944019411071
   PubMed Web of Science ®Google Scholar
• Lee-HoeflichSTCrockerLYaoEA central role for HER3 in HER2-amplified breast cancer: implications for targeted therapyCancer Res200868145878588718632642
   PubMed Web of Science ®Google Scholar
• HennessyBTSmithDLRamPTLuYMillsGBExploiting the PI3K/AKT pathway for cancer drug discoveryNat Rev Drug Discov2005412988100416341064
   PubMed Web of Science ®Google Scholar
• Stemke-HaleKGonzalez-AnguloAMLluchAAn integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancerCancer Res200868156084609118676830
   PubMed Web of Science ®Google Scholar
• CarptenJDFaberALHornCA transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature2007448715243944417611497
   PubMed Web of Science ®Google Scholar
• GainorJFVargheseAMOuSHALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancerClin Cancer Res201319154273428123729361
   PubMed Web of Science ®Google Scholar
• SaalLHHolmKMaurerMPIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinomaCancer Res20056572554255915805248
   PubMed Web of Science ®Google Scholar
• Pérez-TenorioGAlkhoriLOlssonBPIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancerClin Cancer Res200713123577358417575221
   PubMed Web of Science ®Google Scholar
• EstevaFJGuoHZhangSPTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancerAm J Pathol201017741647165620813970
   PubMed Web of Science ®Google Scholar
• RazisEBobosMKotoulaVEvaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancerBreast Cancer Res Treat2011128244745621594665
   PubMed Web of Science ®Google Scholar
• PangBChengSSunSPPrognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysisSci Rep20144625525176561
   PubMed Web of Science ®Google Scholar
• MaruyamaNMiyoshiYTaguchiTTamakiYMondenMNoguchiSClinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese womenClin Cancer Res2007132 Pt 140841417202311
   PubMed Web of Science ®Google Scholar
• BarbareschiMButtittaFFelicioniLDifferent prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomasClin Cancer Res200713206064606917947469
   PubMed Web of Science ®Google Scholar
• KalinskyKJacksLMHeguyAPIK3CA mutation associates with improved outcome in breast cancerClin Cancer Res200915165049505919671852
   PubMed Web of Science ®Google Scholar
• AbramsonVGCooper LloydMBallingerTCharacterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profilingBreast Cancer Res Treat2014145238939924722917
   PubMed Web of Science ®Google Scholar
• CizkovaMSusiniAVacherSPIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroupsBreast Cancer Res2012141R2822330809
   PubMed Web of Science ®Google Scholar
• Ramirez-ArdilaDEHelmijrJCLookMPHotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifenBreast Cancer Res Treat20131391394923592373
   PubMed Web of Science ®Google Scholar
• López-KnowlesESegalCVGaoQRelationship of PIK3CA mutation and pathway activity with antiproliferative response to aro-matase inhibitionBreast Cancer Res2014163R6824981670
   PubMed Web of Science ®Google Scholar
• BeelenKOpdamMSeversonTMPIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patientsBreast Cancer Res2014161R1324467828
   PubMed Web of Science ®Google Scholar
• LoiSMichielsSLambrechtsDSomatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancerJ Natl Cancer Inst20131051396096723739063
   PubMedGoogle Scholar
• Gonzalez-AnguloAMStemke-HaleKPallaSLAndrogen receptor levels and association with PIK3CA mutations and prognosis in breast cancerClin Cancer Res20091572472247819276248
   PubMed Web of Science ®Google Scholar
• EllisMJLinLCrowderRPhosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancerBreast Cancer Res Treat2010119237939019844788
   PubMed Web of Science ®Google Scholar
• LazaridisGLambakiSKarayannopoulouGPrognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancerStrahlenther Onkol2014190763663864064524658605
   PubMed Web of Science ®Google Scholar
• HashimotoKTsudaHKoizumiFActivated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancerAnn Oncol201425101973197925009009
   PubMed Web of Science ®Google Scholar
• BozhanovSSAngelovaSGKrastevaMEAlterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancerJ Cancer Res Clin Oncol2010136111657166920177704
   PubMed Web of Science ®Google Scholar
• JensenJDKnoopALaenkholmAVPIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumabAnn Oncol20122382034204222172323
   PubMed Web of Science ®Google Scholar
• LiuYRJiangYZZuoWJYuKDShaoZMPIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysisOnco Targets Ther2014754355224748804
   PubMed Web of Science ®Google Scholar
• XuBGuanZShenZAssociation of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel aloneBreast Cancer Res201416440525056500
   PubMed Web of Science ®Google Scholar
• BaderAGKangSVogtPKCancer-specific mutations in PIK3CA are oncogenic in vivoProc Natl Acad Sci U S A200610351475147916432179
   PubMed Web of Science ®Google Scholar
• ZhaoLVogtPKHelical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanismsProc Natl Acad Sci U S A200810572652265718268322
   PubMed Web of Science ®Google Scholar
• BernsKHorlingsHMHennessyBTA functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerCancer Cell200712439540217936563
   PubMed Web of Science ®Google Scholar
• EichhornPJGiliMScaltritiMPhosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235Cancer Res200868229221923019010894
   PubMed Web of Science ®Google Scholar
• KataokaYMukoharaTShimadaHSaijoNHiraiMMinamiHAssociation between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell linesAnn Oncol201021225526219633047
   PubMed Web of Science ®Google Scholar
• O’BrienNABrowneBCChowLActivated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinibMol Cancer Ther2010961489150220501798
   PubMed Web of Science ®Google Scholar
• CizkovaMDujaricMELehmann-CheJOutcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumabBr J Cancer201310891807180923612454
   PubMed Web of Science ®Google Scholar
• Pogue-GeileKLSongNJeongJHIntrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 TrialJ Clin Oncol Epub152015
   Web of Science ®Google Scholar
• LoiblSvon MinckwitzGSchneeweissAPIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancerJ Clin Oncol201432293212322025199759
   PubMed Web of Science ®Google Scholar
• MajewskiIJNuciforoPMittempergherLPIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancerJ Clin Oncol Epub152015
   PubMed Web of Science ®Google Scholar
• ToiMIwataHFujiwaraYLapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studiesBr J Cancer2009101101676168219844234
   PubMed Web of Science ®Google Scholar
• SchneeweissAChiaSHeggREvaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and tras-tuzumab-based therapy: an exploratory analysis of the TRYPHAENA studyBreast Cancer Res2014164R7325005255
   PubMed Web of Science ®Google Scholar
• BaselgaJCortésJKimSBPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875
   PubMed Web of Science ®Google Scholar
• BaselgaJCortesJImSABiomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancerJ Clin Oncol201432333753376125332247
   PubMed Web of Science ®Google Scholar
• CampbellRABhat-NakshatriPPatelNMConstantinidouDAliSNakshatriHPhosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistanceJ Biol Chem2001276139817982411139588
   PubMed Web of Science ®Google Scholar
• MohseniMParkBHPIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001J Clin Invest201012082655265820664174
   PubMed Web of Science ®Google Scholar
• MillerTWRexerBNGarrettJTArteagaCLMutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancerBreast Cancer Res201113622422114931
   PubMed Web of Science ®Google Scholar
• JankuFWhelerJJNaingAPIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trialsCancer Res201373127628423066039
   PubMed Web of Science ®Google Scholar
• BaselgaJBradburyIEidtmannHLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialLancet2012379981663364022257673
   PubMed Web of Science ®Google Scholar
• BerrutiAAmorosoVGalloFPathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studiesJ Clin Oncol201432343883389125349292
   PubMed Web of Science ®Google Scholar